| |
Centre for Policy on Ageing | |
 | |
|
| New treatment for Alzheimer's disease | | Corporate Author | Alzheimer's Disease Society |
| Publisher | Alzheimer's Disease Society, London, April 1997 |
| Pages | 4 pp (Information sheet 11) |
| Source | Alzheimer's Disease Society, Gordon House, 10 Greencoat Place, London SW1P 1PH. |
| Keywords | Dementia ; Drugs. |
| Annotation | Alzheimer's disease (AD) is a progressive disorder of the brain, in which the ability to remember and reason gradually deteriorates. These changes are due to the destruction of brain cells, particularly those situated in the higher centres of the brain. The causes of the disease remain unknown, and it has so far proved impossible to stop the deterioration through the use of drugs. This information sheet gives information on donepezil hydrochlorine (Aricept TM or E 2020) and tacrine. Exelon (SDZ ENA 713), metrifonate, and galanthamine are three other drugs being tested in clinical trials which may become available in 1998; and there are some 300 drugs for AD currently under development. |
| Accession Number | CPA-971212217 P |
| Classmark | EA: LLD |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|